Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
R&D Systems™ Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 2017T2050
This item is not returnable. View return policy
SDSDocumentsProduct Certifications Promotions
DescriptionMeasured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Immobilized Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera at 5 μg/mL, 100 μL/well can support 60-80% HSB2 cell adhesion, when 1 x 105 cells were added in each well of a 96-well plate.
|Lyophilized from a 0.2 µm filtered solution in PBS.|
|M.W. (Observed): 106 kDa, reducing conditions; M.W. (theoretical): 73.8 kDa (monomer)|
|>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.|
|Mouse myeloma cell line, NS0-derived human LILRB1/CD85j/ILT2 protein Human LILRB1/CD85j/ILT2 (Gly24-His458) (N-terminus) Accession # Q8NHL6 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
|ILT2/CD85j Fc Chimera|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|<0.10 EU / 1 µg of the protein by the LAL method.|
|Reconstitute at 100 µg/mL in sterile PBS.|
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok